


In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-26. (Canceled)

27. (Currently amended) A compound peptide which binds to a DM2 protein, which compound peptide comprises an amino acid motif comprising at least the eight consecutive amino acids from F to R<sub>4</sub> of the formula



wherein

R<sub>1</sub> is a proline (P), leucine (L), glutamic acid (E), cysteine (C) or glutamine (Q), X stands for any natural amino acid,

R<sub>2</sub> is arginine (R), histidine (H), glutamic acid (E), cysteine (C), serine (S), or aspartic acid (D),

R<sub>3</sub> is histidine (H), phenylalanine (F) or tyrosine (Y),

R<sub>4</sub> is phenylalanine (F), glutamine (Q) or leucine (L); and

F is phenylalanine and W is tryptophan,

and inhibits the binding of said DM2 protein to a p53 protein.

28. (Currently amended) The compound peptide according to claim 27 wherein the compound peptide binds to human DM2 (HDM2).

29. (Currently amended) The compound peptide according to claim 27, further comprising which is coupled to a biotin moiety ~~coupled to the amino-acid motif~~.

30. (Currently amended) The compound peptide according to claim 27, which is ~~wherein the amino-acid motif comprises~~ a cyclic peptide.

31. (Currently amended) The compound peptide according to claim 27, wherein ~~the amino-acid motif comprises~~ which is a cyclic lactam.

32. (Currently amended) The compound peptide according to claim 27 ~~wherein the amino-acid motif which~~ comprises a disulfide bond.

33. (Currently amended) The compound peptide according to claim 27 which comprises no more than fifteen amino acids (15 mers).

34. (Currently amended) The compound peptide according to claim 27 which comprises an amino acid motif selected from the group consisting of M-P-R-F-M-D-Y-W-E-G-L-N (SEQ ID NO: 6), Q-P-T-F-S-D-Y-W-K-L-L-P (SEQ ID NO: 7), and P-X-F-X-D-Y-W-X-X-L (SEQ ID NO: 8).

35. (Currently amended) ~~The compound according to claim 27, A peptide~~ which comprises eight amino acids according to the formula

F-X2-R2-R3-W-X3-X4-R4 (Ib) (SEQ ID NO: 10)

wherein R2 is arginine (R), histidine (H), glutamic acid (E), cysteine (C), serine (S), or aspartic acid (D);

R3 is histidine (H), phenylalanine (F), or tyrosine (Y);

R4 is phenylalanine (F), gutamine glutamine (Q) or leucine (L);

X2 is methionine (M), isoleucine (I), threonine (T), arginine (R), alanine (A) or serine (S);

X3 is glutamic acid (E), threonine (T), alanine (A), phenylalanine (F) or serine (S); and X4 is glycine (G), glutamine (Q), threonine (T), alanine (A) or aspartic acid (D).

36. (Currently amended) The compound peptide according to claim 27 35 comprising an amino acid motif of the formula

X1-F-X2-R2-R3-W-X3-X4-R4 (Ic) (SEQ ID NO: 11)

wherein

R2 is arginine (R), histidine (H), glutamic acid (E), cysteine cysteine (C), serine (S), or aspartic acid (D);

R3 is histidine (H), phenylalanine (F) or tyrosine (Y);

R4 is phenylalanine (F), glutamine (Q) or leucine (L);

X1 is arginine (R), asparagine (N), alanine (A), threonine (T), or valine (V);

X2 is methionine (M), isoleucine (I), threonine (T), arginine (R), alanine (A), or serine (S);

X3 is glutamic acid (E), threonine (T), alanine (A), phenylalanine (F), or serine (S); and  
X4 is glycine (G), glutamine (Q), threonine (T), alanine (A), or aspartic acid (D).

37. (Canceled)

38. (Currently amended) The compound peptide according to claim 27, wherein R2 is aspartic acid (D).

39. (Currently amended) The compound peptide according to claim 35, wherein at least one of R2, X2, X3, and X4 is defined as follows: R2 is aspartic acid (D), X2 is methionine (M), X3 is glutamic acid (E), and X4 is glycine (G).

40. (Currently amended) The compound peptide according to claim 36, wherein at least one of R2, X1, X2, X3, and X4 is defined as follows: R2 is aspartic acid (D), X1 is arginine (R), X2 is methionine (M), X3 is glutamic acid (E), and X4 is glycine (G).

41. (Currently amended) A method for inhibiting the binding of a DM2 protein to a p53 protein comprising contacting said DM2 protein with a compound peptide which compound peptide comprises an amino acid motif comprising at least eight consecutive amino acids of the formula

R<sub>1</sub>-X-F-X-R<sub>2</sub>-R<sub>3</sub>-W-X-X-R<sub>4</sub> (I) ( SEQ ID NO: 4)

wherein

R<sub>1</sub> is a proline (P), leucine (L), glutamic acid (E), cysteine (C) or glutamine (Q),  
X stands for any natural amino acid,

R<sub>2</sub> is arginine (R), histidine (H), glutamic acid (E), cysteine (C), serine (S), or aspartic acid (D),

R<sub>3</sub> is histidine (H), phenylalanine (F) or tyrosine (Y),

R<sub>4</sub> is phenylalanine (F), glutamine (Q) or leucine (L); and

F is phenylalanine and W is tryptophan,

and inhibits the binding of said DM2 protein to a p53 protein.

42. (Previously presented) The method of claim 41 wherein R2 is aspartic acid (D).

43-51. (Canceled)

52. (Currently amended) A composition comprising a compound peptide, which compound peptide comprises an amino acid motif comprising at least eight consecutive amino acids of the formula

$R_1-X-F-X-R_2-R_3-W-X-X-R_4$  (I) ( SEQ ID NO: 4)

wherein

$R_1$  is a proline (P), leucine (L), glutamic acid (E), cysteine (C) or glutamine (Q),

X stands for any natural amino acid,

$R_2$  is arginine (R), histidine (H), glutamic acid (E), cysteine (C), serine (S), or aspartic acid (D),

$R_3$  is histidine (H), phenylalanine (F) or tyrosine (Y),

$R_4$  is phenylalanine (F), glutamine (Q) or leucine (L); and

F is phenylalanine and W is tryptophan,

and inhibits the binding of said DM2 protein to a p53 protein, in admixture with at least one pharmaceutically acceptable carrier.